Cannabinoids Reduce Extracellular Vesicle Release from HIV-1 Infected Myeloid Cells and Inhibit Viral Transcription

Area of Science:

• Neuroscience
• Virology
• Immunology

Background:

• Human immunodeficiency virus type 1 (HIV-1) infection affects millions globally, with about 50% experiencing HIV-associated neurocognitive disorders (HAND).
• HIV-1 viral RNAs are packaged into extracellular vesicles (EVs), triggering inflammation in recipient cells.
• Cannabinoids like Cannabidiol (CBD) show anti-inflammatory properties and cannabis use is linked to better outcomes in people with HIV-1.

Purpose of the Study:

• To investigate the therapeutic potential of CBD in mitigating HIV-1 pathogenesis, particularly concerning EV production and neuroinflammation.
• To assess CBD's impact on viral RNA within cells and EVs, and its effect on autophagy pathways.

Main Methods:

• Utilized HIV-1 infected U1 monocytes and primary macrophages for experiments.
• Analyzed EV concentrations using nanoparticle tracking analysis post-CBD treatment.
• Quantified intracellular and EV-associated viral RNA via RT-qPCR and assessed protein changes using Western blot.

Main Results:

• CBD treatment significantly reduced the number of EVs released from HIV-1 infected cells.
• CBD appeared to decrease viral transcription and autophagy activation, key factors in EV production.
• These effects suggest a mechanism by which CBD may reduce pathogenic EV-mediated effects.

Conclusions:

• CBD demonstrates a potential protective role in HIV-1 infection by reducing the release of pathogenic EVs.
• CBD may alleviate neuroinflammation and neurocognitive decline associated with HIV-1 by targeting viral RNA and autophagy.
• Further research into CBD as a therapeutic agent for HIV-1 and central nervous system (CNS) complications is warranted.